Literature DB >> 34461138

Transcriptomic and proteomic analyses of venom glands from scorpions Liocheles australasiae, Mesobuthus martensii, and Scorpio maurus palmatus.

Wai Lok So1, Thomas C N Leung2, Wenyan Nong1, William G Bendena3, Sai Ming Ngai4, Jerome H L Hui5.   

Abstract

Scorpion venom contains a cocktail of differing peptides and proteins. Previous studies focused on the identification of species-specific components in scorpion venoms, and whether there could be peptides and/or proteins conserved in the venom gland of a scorpion ancestor has been rarely investigated. Here, using a combination of transcriptomic and proteomic approaches, putative conserved toxins from the venom glands of scorpions Liocheles australasiae, Mesobuthus martensii, and Scorpio maurus palmatus were identified and compared. Similar to other studies, more than half of the conserved toxins are predominantly proteins including proteases. On the other hand, unique venom peptides, including ion channel toxins were revealed specifically in the M. martensii. The sodium channel toxin peptides revealed in M. martensii consolidated that scorpions in the Buthidae are able to envenomate their prey wih highly neurotoxic venom. This study suggested that these conserved proteins had already formed part of the arsenal in the venom gland of the common ancestor of scorpions, and likely perform important functional roles in envenomation during scorpion evolution.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Envenomation; Evolution; Scorpion; Sodium channel toxin; Toxin peptides; Venom gland

Mesh:

Substances:

Year:  2021        PMID: 34461138     DOI: 10.1016/j.peptides.2021.170643

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  1 in total

1.  Astragalus-Scorpion Drug Pair Inhibits the Development of Prostate Cancer by Regulating GDPD4-2/PI3K/AKT/mTOR Pathway and Autophagy.

Authors:  Xujun You; Yongrong Wu; Qixin Li; Wen Sheng; Qing Zhou; Wei Fu
Journal:  Front Pharmacol       Date:  2022-06-29       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.